Please use this identifier to cite or link to this item:
Title: The dopamine metabolite 3-methoxytyramine is a neuromodulator
Authors: Sotnikova, T.D.
Beaulieu, J.-M.
Espinoza, S.
Masri, B.
Zhang, X. 
Salahpour, A.
Barak, L.S.
Caron, M.G.
Gainetdinov, R.R.
Issue Date: 2010
Citation: Sotnikova, T.D., Beaulieu, J.-M., Espinoza, S., Masri, B., Zhang, X., Salahpour, A., Barak, L.S., Caron, M.G., Gainetdinov, R.R. (2010). The dopamine metabolite 3-methoxytyramine is a neuromodulator. PLoS ONE 5 (10) : -. ScholarBank@NUS Repository.
Abstract: Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3- methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent manner and these effects are partially mediated by the trace amine associated receptor 1 (TAAR1). Unbiased in vivo screening of putative trace amine receptor ligands for potential effects on the movement control revealed that 3-MT infused in the brain is able to induce a complex set of abnormal involuntary movements in mice acutely depleted of dopamine. In normal mice, the central administration of 3-MT caused a temporary mild hyperactivity with a concomitant set of abnormal movements. Furthermore, 3-MT induced significant ERK and CREB phosphorylation in the mouse striatum, signaling events generally related to PKA-mediated cAMP accumulation. In mice lacking TAAR1, both behavioral and signaling effects of 3-MT were partially attenuated, consistent with the ability of 3-MT to activate TAAR1 receptors and cause cAMP accumulation as well as ERK and CREB phosphorylation in cellular assays. Thus, 3-MT is not just an inactive metabolite of DA, but a novel neuromodulator that in certain situations may be involved in movement control. Further characterization of the physiological functions mediated by 3-MT may advance understanding of the pathophysiology and pharmacology of brain disorders involving abnormal dopaminergic transmission, such as Parkinson's disease, dyskinesia and schizophrenia. © 2010 Sotnikova et al.
Source Title: PLoS ONE
ISSN: 19326203
DOI: 10.1371/journal.pone.0013452
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.